Astellas acts to block Sandoz's generic Prograf in Canada
This article was originally published in Scrip
Astellas has taken legal action against Sandoz in Canada after the Novartis generics operation filed an abbreviated submission for the approval of its generic version of Prograf (tacrolimus).
You may also be interested in...
Product review report reveals multiple delays and missteps on route to market, holding valuable lessons for other gene therapy developers but also evidencing an ultimately welcoming environment.
Join us for a quick audio roundup of major developments in the international biopharma industry over the past week, as covered by Scrip's global team.
Positive clinical results pave path forward for Japanese firm’s potential istradefylline successor.